The Rheumatology Network lupus clinical focus page provides information on the latest lupus news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for systemic lupus erythematosus drugs.
August 19, 2022
"Chronic cutaneous lupus erythematosus is prone to cause substantial disfigurement on visible skin, negatively impacting patients’ mental health and social life."
August 17, 2022
Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.
August 11, 2022
"An unmet need is a biomarker that distinguishes active lupus nephritis, particularly important in pediatrics where minimizing invasive procedures is desirable.”
July 29, 2022
Although a third dose of mRNA vaccine significantly increased antireceptor-binding domain (RBD) titer in a previous study, clinical factors associated with the immunogenicity in immunosuppressed populations have not been adequately studied.
July 28, 2022
Despite advancements over the years, cutaneous lupus erythematosus (CLE) continues to represent a high unmet medical need with no cure.
July 27, 2022
The US FDA has approved belimumab for the treatment of active lupus nephritis in children aged 5 to 17 who are currently receiving standard therapy.
July 21, 2022
25% of patients presented with extensive blood-brain barrier leakage, which was linked to both cognitive impairment and shorter disease duration.
July 20, 2022
Previous assessments of the prevalence of lupus were conducted in short periods of time, therefore limiting the insight into long-term trends and potential explanations for the observed patterns.
July 18, 2022
As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.
July 13, 2022
Additional doses improved seroconversion and most vaccinated patients with lupus experienced a generally mild course of the disease.